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state level used unpublished narrative lists of indications to
define “medical necessity.” However, in the mid-1990s,
with the mandate for electronic submission, Medicare car-
riers implemented International Classification of Diseases
(ICD-9) codes to define what is “medically necessary and
reasonable” according to “accepted medical standards.”
As of December 27, 1996, local medical review policy
(LMRP) has defined noninvasive vascular diagnostic stud-
ies to include “patient care required to perform the stud-
ies, supervision of the studies, and interpretation of study
results,” placing the responsibility on the provider “to
ensure the medical necessity of procedures and to appro-
priately document the medical record.”3 Although ICD-9
codes that support “medical necessity” for the ordering of
noninvasive vascular diagnostic studies were implemented
at that time and have since undergone several revisions,
the impact of these Medicare coverage limitations and
claim denials based on compliance rules for “medical
necessity” on noninvasive vascular diagnostic testing has
not been reported.
METHODS
The hospital billing computer database at Vanderbilt
University Medical Center in Nashville, Tennessee, was
queried for tests performed in the clinical vascular labora-
tory. All Medicare claims for noninvasive vascular diagnos-
tic studies performed between January 1, 1999, and
December 31, 1999, were identified according to Current
Procedural Terminology (CPT) codes for carotid artery
duplex ultrasound scans (93880, 93882), venous duplex
ultrasound scans (93970, 93971), and lower-extremity
Title XVIII of the Social Security Act, Section 1862
(a)(1)(A) excludes coverage for “items or services that are
not reasonable and necessary for the diagnosis or treat-
ment of illness or injury or to improve the functioning of
a malformed body member.”1 Health Care Financing
Administration (HCFA) Ruling No. 95-1 from December
1995 states that the policy…concerning the requirements
for determining if Medicare payment will be made under
the limitation on liability provisions, section 1879 of the
Social Security Act, to a provider, practitioner, or other
supplier for certain services and items for which Medicare
payment is denied.2
Effectively, this ruling more directly allowed HCFA to
enforce limitation of coverage by allowing payment under
the Medicare program only for those services that are con-
sidered to be “medically necessary and reasonable in
accordance with accepted medical standards.”
Before the mid-1990s, many insurance companies
contracted by HCFA to process Medicare claims at the
846
From the Division of Vascular Surgery, Department of Surgery, Vanderbilt
University Medical Center, Nashville, Tennessee.
Competition of interest: nil.
Presented at the Twenty-ninth Annual Symposium of the Society for
Clinical Vascular Surgery, Boca Raton, Fla, April 4-8, 2001.
Reprint requests: Marc A. Passman, MD, Division of Vascular Surgery,
Vanderbilt University Medical Center, 1161 22nd Ave, South, D-5237
MCN, Nashville, TN 37232-2735 (e-mail: marc.passman@surgery.
mc.vanderbilt.edu).
Copyright © 2001 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2001/$35.00 + 0 24/6/119229
doi:10.1067/mva.2001.119229
Impact of Medicare denials on noninvasive
vascular diagnostic testing
Marc A. Passman, MD, Raul J. Guzman, MD, Rosanna Pierce, RN, RVT, and Thomas C. Naslund,
MD, Nashville, Tenn
Purpose: The purpose of this study was to evaluate the impact of Medicare coverage limitations and claim denials on
noninvasive vascular diagnostic testing.
Methods: All Medicare claims for noninvasive vascular diagnostic studies from January 1, 1999, to December 31, 1999,
were identified from the hospital billing database according to Current Procedural Terminology codes for carotid
artery duplex ultrasound scan, venous duplex ultrasound scan, and lower-extremity arterial Doppler scan. Reasons for
Medicare denial of payment for these tests were reviewed and a cost analysis was performed.
Results: During the 1-year period, there were 1096 noninvasive vascular diagnostic studies performed on Medicare
patients. Of these 1096 tests, 176 (16.1%) were denied by Medicare (19.6% of 408 carotid duplex ultrasound scans,
16.8% of 345 venous duplex ultrasound scans, and 11.1% of 343 lower-extremity arterial Doppler scans). Of the non-
invasive vascular tests denied by Medicare, an abnormal result was present in 72.5% of carotid duplex ultrasound scans,
32.8% of venous duplex ultrasound scans, and 78.9% of lower-extremity arterial Doppler scans. Overall, 88.1% of all
initially denied claims (N = 176) were ultimately reimbursed by Medicare after resubmission, including 77.1% of the
118 claims denied based on compliance rules for “medical necessity.”
Conclusion: Because of coverage limitations, Medicare denials of noninvasive vascular diagnostic tests can lead to poten-
tial uncompensated physician and hospital technical fees if denied claims are unrecognized. Vascular laboratories per-
forming these tests need to review compliance with Medicare guidelines. Improvements may need to be made at both
the provider and Medicare carrier levels in obtaining reimbursement for appropriately ordered noninvasive vascular
diagnostic studies. (J Vasc Surg 2001;34:846-53.)
arterial Doppler scans (93923, 93924).4 Medicare claim
denials for noninvasive vascular diagnostic studies were
identified based on institutional denial codes assigned by
the billing office, and reasons for Medicare denial of pay-
ment denial were stratified.
Medical records and ICD-9 codes used for Medicare
claims submissions at the time of noninvasive vascular diag-
nostic testing were retrospectively reviewed. Submitted
ICD-9 codes for each noninvasive vascular diagnostic study
performed were correlated with the “ICD-9 codes that
support medical necessity” based on the LMRP as listed by
the local Medicare carrier for the state of Tennessee during
the same time period (Riverbend-BlueCross/BlueShield of
Tennessee for submission of technical charges to Medicare
Part A and CIGNA HealthCare Medicare Administration
for submission of professional charges to Medicare Part B)
(Appendixes 1, 2, 3).3,5 Correlation with clinical indica-
tions from the medical record was performed, and results
from noninvasive vascular diagnostic studies that were
denied by Medicare were reviewed.
Cost analysis was performed based on both charges
and the Medicare reimbursement schedule from 1999 for
hospital technical fees and physician fees. Potential uncol-
lected reimbursement and uncompensated vascular labo-
ratory technologist time were calculated and analyzed
based on total cost expenditure for the noninvasive vascu-
lar laboratory during the same period. Because under
Medicare policy, the technical component for inpatient
studies is bundled into the Diagnosis Related Grouping
payment for the hospitalization, technical fees for inpa-
tient studies were excluded from cost analysis.
RESULTS
During the 1-year period, there were 1096 noninvasive
vascular diagnostic studies performed on Medicare patients.
Overall, 176 (16.1%) of these tests were initially denied pay-
ment by Medicare. Medicare denials included 80 of 408
carotid duplex ultrasound scans (19.6%), 58 of 345 venous
duplex ultrasound scans (16.8%), and 38 of 343 lower-
extremity arterial Doppler scans (11.1%). Of the 176
Medicare denials, 165 (93.8%) tests had been performed on
outpatients, and 11 (6.2%) on hospital inpatients.
Reasons for Medicare denials are listed in Table I.
Overall, 118 claims had been submitted with ICD-9 codes
that did not support “medical necessity”, accounting for
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67.0% of all Medicare denials. After stratification based on
noninvasive vascular diagnostic study, 71.3% of carotid
duplex ultrasound scans, 43.1% of venous duplex ultra-
sound scans, and 63.2% of lower-extremity arterial
Doppler scans were denied based on LMRP compliance
rules for “medical necessity.”
Of the noninvasive vascular diagnostic studies initially
denied by Medicare, an abnormal result was present in
107 (60.8%). Abnormal findings were present in 72.5% of
carotid duplex ultrasound scans, 32.8% of venous duplex
ultrasound scans, and 78.9% of lower-extremity arterial
Doppler scans (Tables II, III, IV).
Based on institutional charges from 1999, these
Medicare denials (N = 176) represent $53,068 of hospital
technical charges and $19,645 of physician charges. Using
the Medicare reimbursement fee schedule from 1999,
these Medicare denials account for $5,475 of potential
uncollected physician fees and $18,356 of potential uncol-
lected hospital technical fees. Medicare reimbursement
would have covered 80% of these fees, resulting in $4380
and $14,685, respectively, of potential lost revenue from
Medicare coverage. Based on total gross expenditures for
1999 of the clinical vascular laboratory, potential uncol-
lected hospital technical fees represented 8.1% and poten-
tial lost revenue from Medicare represented 6.4% of the
overall operating budget ($227,989). According to the
average time of completion for each test, Medicare denials
Table I. Reason for Medicare denial for noninvasive vascular diagnostic study (N = 176)
Carotid duplex Venous duplex Lower-extremity arterial
Reason for denial ultrasound scan (n = 80) ultrasound scan (n = 58) Doppler scan (n = 38)
ICD-9 code does not meet “medical necessity” 59 33 26
Duplicate claim 6 5 4
Policy not in effect, not insured, or not authorized 4 4 4
Claim data requested 2 5 2
Error on claim submission 4 8 2
Miscellaneous other 5 3 0
Table II. Results of carotid duplex ultrasound scans




ICA stenosis 16%-49% 18
ICA stenosis 50%-79% 48
ICA stenosis 80%-99% 4
ICA occlusion 6
Isolated ECA stenosis 8
Isolated CCA stenosis 3
Subclavian stenosis/occlusion 38
Vertebral stenosis/occlusion 6
*Includes 78 bilateral and 2 unilateral carotid duplex ultrasound scans.
†Findings are based on abnormalities in arteries studied.
ICA, Internal carotid artery; ECA, external carotid artery; CCA, common
carotid artery.
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represented an additional 96 hours of potential uncom-
pensated clinical vascular laboratory technologist time.
After Medicare denials were identified, claims were
resubmitted. For claims that were denied because of
LMRP compliance rules for “medical necessity,” appropri-
ate changes were made and proper documentation was
provided. All claims denied for other reasons were also
resubmitted after corrections were made. Overall, 88.1%
of all initially denied claims (N = 176) were ultimately
reimbursed by Medicare, including 77.1% of the 118
claims denied based on LMRP compliance rules for “med-
ical necessity.” Hospital billing office time and cost
required for Medicare denial resubmission was not quan-
tifiable and was not factored into the cost analysis.
DISCUSSION
Since Medicare was enacted in 1965, its functions have
extended well beyond its basic mission of providing health
insurance to persons older than 65 years and persons with
disabilities. With Medicare enrollees approaching 40 million,
Medicare expenditures have grown rapidly since its incep-
tion. Since the mid-1980s, slowing the growth of Medicare
spending has been a high priority for Congress. During the
past decade, federal legislation such as the Omnibus Budget
Reconciliation Act of 1989, the Paperwork Reduction Act
of 1995, the Health Insurance and Accountability Act of
1996, the Balanced Budget Act of 1997, and Balanced
Budget Refinement Act of 1999 have addressed several
determinants of cost, ie, reimbursement for services, admin-
istrative costs, fraudulent claims, and number of services
provided. Clearly, the largest impact on the practice of vas-
cular surgery from these legislative acts is related to the reor-
ganization of a revised fee schedule based on Resource-
Based Relative Value Scale, the net fiscal impact of which has
yet to be completely realized.6-8 While restructuring of the
fee schedule based on Resource-Based Relative Value Scale
initially undervalued noninvasive vascular diagnostic testing
by eliminating the technical component of reimbursement,
this problem has been previously addressed.9 However, sig-
nificant efforts to decrease Medicare expenditures have also
extended into reduction of resource use, and the impact of
these coverage limitations on noninvasive vascular diagnos-
tic testing remains unknown.
In an effort to reduce the use of services considered to
be inappropriate and to reduce cost, HCFA has allowed
the establishment of guidelines to distinguish between
appropriate and inappropriate care. This has evolved to
enforcement of coverage limitation by allowing payment
under the Medicare program according to ICD-9 codes
only for those services that are considered to be “medically
necessary and reasonable in accordance with accepted
medical standards.” Although in the early 1990s noninva-
sive vascular laboratories were somewhat unregulated,
through the efforts of various Vascular Societies and with
the creation of the Intersocietal Commission for the
Accreditation of Vascular Laboratories, guidelines and
standards have become established.10 Many of the recom-
mendations provided to the Medicare Carrier Medical
Directors group were incorporated into the initial stand-
ards used by individual Medicare carriers for defining what
is medically acceptable.11 Although these initial guidelines
were more general in scope, as of 1996 these standards
have evolved into the current system followed by local
Medicare carriers that uses “ICD-9 codes that support
medical necessity” to define appropriate and inappropriate
noninvasive vascular diagnostic testing.
Although coverage limitations and compliance rules
defining “medical necessity” for noninvasive vascular diag-
nostic testing have been established, the appropriateness of
these standards requires review. In this study, 16.1% of
noninvasive vascular diagnostic tests performed (N = 176)
were denied by Medicare during a 1-year period, including
19.6% of carotid duplex ultrasound scans, 16.8% of venous
duplex ultrasound scans, and 11.1% of lower-extremity
arterial Doppler scans, with 67.0% of all Medicare denials
initially submitted with ICD-9 codes that did not support
“medical necessity.” Of the noninvasive vascular tests ini-
tially denied by Medicare, an abnormal result was present
in 72.5% of carotid duplex ultrasound scans, 32.8% of
venous duplex ultrasound scans, and 78.9% of lower-
extremity arterial Doppler scans, representing potentially
missed disease states. Although in some ways these cover-
age limitations and compliance rules for “medical neces-
sity” do eliminate inappropriately ordered tests, the
significant proportion of patients with documented vascu-
lar disease within this Medicare denial group raises the
question of whether the current use of “ICD-9 codes that
support medical necessity” is adequate to define what is
Table III. Results of venous duplex ultrasound scans







*Includes 32 bilateral and 26 unilateral venous duplex ultrasound scans.
†Findings are based on abnormalities in extremities studied.
Table IV. Results of lower-extremity arterial Doppler







Noncompressible with severe disease 5
*Includes 33 bilateral and 5 unilateral lower-extremity arterial Doppler
scans.
†Findings are based on abnormalities in lower extremities studied.
ABI, Ankle brachial index.
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and what is not “reasonable and necessary.” Although
77.1% of the 118 claims denied because of “medical neces-
sity” guidelines were ultimately reimbursed, improvements
need to be made in obtaining reimbursement for appropri-
ately ordered tests. This involves both improved under-
standing and implementation at the provider level of
Medicare compliance rules and expanding appropriate
ICD-9 codes that may not meet the current compliance
rules for “medical necessity.” Although the original LMRP
in the state of Tennessee outlining the “ICD-9 codes that
support medical necessity” were defined in December
1996, they have since been revised in March 1999,
December 1999, April 2000, and November 2000. It is
imperative for all practitioners who rely on the noninvasive
vascular laboratory to participate in the review process so
that coverage will improve and appropriately ordered tests
can be reimbursed.
In addition to the pressure from reduced payments for
service, the increased financial burden of Medicare denials
on noninvasive vascular laboratories is important as well.
Overall, these Medicare denials accounted for $5475 of
potential uncollected physician fees and $18,356 of poten-
tial uncollected hospital technical fees based on the 1999
Medicare reimbursement fee schedule, which represented
$4,380 and $14,685, respectively, of potential lost rev-
enue from Medicare. Potential uncollected hospital tech-
nical fees accounted for 8.1% and lost revenue from
Medicare accounts for 6.4% of the clinical vascular labora-
tory fiscal budget for that year. These Medicare denials
represented an additional 96 hours of potential uncom-
pensated noninvasive peripheral vascular laboratory tech-
nologist time.
There are several assumptions made in this cost analy-
sis. First, Medicare claim denials for noninvasive vascular
diagnostic studies were identified based on institutional
denial codes for professional billing only. Hospital techni-
cal claim denials could not be directly identified from the
hospital billing system. Therefore, cost analysis assumes a
parallel denial rate for both hospital technical and profes-
sional billing. In reality, the technical Medicare claim
denial rate is unknown, but most likely is closely approxi-
mated by the professional claim denial rate because similar
guidelines are used by the LMRP for Medicare Part A and
Part B in the state of Tennessee. Second, although 88.1%
of all initially denied claims were ultimately reimbursed by
Medicare, hospital billing office time and cost required for
Medicare denial resubmission was not factored into this
cost analysis. Thus, the cost burden for each Medicare
claim denial is potentially higher and beyond just uncol-
lected hospital technical and physician reimbursement.
Medicare will continue to increase its efforts to cut
spending through aggressive review of claims and the use
of new fraud and abuse regulations. According to HCFA
Ruling No. 95-1, “providers, practitioners, and other sup-
pliers are always responsible for knowing locally acceptable
standards of practice; their local licensure is premised on
the assumption that they have such knowledge.”2
Providers must be especially careful to provide cor-
rect procedure codes that define precisely what services
are provided and accurate diagnosis codes that link those
procedures or tests to an appropriate diagnosis. The
problem with some of the Medicare denials in this study
was discrepancies in the ICD-9 codes used by providers
ordering noninvasive vascular diagnostic studies and not
understanding the regulations that govern the use of
“ICD-9 codes that support medical necessity.” When
appropriately coded and resubmitted with the proper
documentation, most of these Medicare denials were
reimbursed.
Based on this study, there are several suggestions
that can decrease the Medicare claim denial rate. First,
educational programs need to be in place to familiarize
all technologists and physicians working in the noninva-
sive vascular laboratory with current regulations for
Medicare compliance. Educational material should also
extend to physicians ordering tests to help select appro-
priate ICD-9 codes. Second, all ICD-9 codes submitted
with ordered noninvasive vascular laboratory tests need
to be cross referenced with current “ICD-9 codes that
support medical necessity” defined by the LMRP.
Providers ordering tests are responsible for the accuracy
of submitted ICD-9 codes and for providing appropriate
documentation to support the requested study. When
compliance rules for “medical necessity” are not ful-
filled, the test should not be performed and the provider
ordering the test needs to be notified. Alternatively, with
the use of an Advance Beneficiary Notice, the patient
can be made aware that Medicare may not pay and that
they may be responsible for payment in the event that
Medicare payment is denied. Third, noninvasive vascular
laboratories must have a mechanism in place that allows
identification and review of Medicare denials followed
by active resubmission with appropriate corrections and
documentation. Finally, all practitioners who rely on the
noninvasive vascular laboratory need to participate in
the LMRP process with the local Medicare carrier to
improve coverage so that appropriately ordered tests can
be reimbursed.
CONCLUSION
Because of coverage limitations and compliance rules
defining “medical necessity,” Medicare denials of noninva-
sive vascular diagnostic studies can lead to uncompensated
physician and hospital technical fees, especially if denied
claims are unrecognized. With a significant portion of
denied noninvasive vascular test results abnormal, improve-
ments need to be made at both the provider and Medicare
carrier levels in obtaining reimbursement for appropriately
ordered tests.
The authors express their gratitude to Cathy E.
Halsey, BA, RHIT, CPC, for her assistance in the prepara-
tion of this manuscript.
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Appendix 1. ICD-9 codes that support medical necessity for carotid artery duplex ultra-
sound scans (CPT 93880, 93882) based on the LMRP as listed by the local Medicare carrier
(BlueCross/BlueShield of Tennessee and CIGNA HealthCare Medicare Administration) for
the state of Tennessee during 19993,5
ICD-9 code
342-342.92 Hemiplegia
344.00-344.52 Quadriplegia and quadriparesis
344.80-344.9 Other specified paralytic syndrome
362.30-362.37 Retinal vascular occlusion
362.84 Retinal ischemia
368.10 Subjective visual disturbance, unspecified
368.11 Sudden visual loss
368.12 Transient visual loss (concentric fading; scintillating scotoma)
368.40-368.47 Visual field defects
433-433.91 Occlusion and stenosis of precerebral arteries (includes embolism, narrowing, 
obstruction, or thrombosis of basilar, carotid, or vertebral arteries)
434.00-434.91 Occlusion of cerebral arteries
435-435.9 Transient cerebral ischemia (includes cerebrovascular insufficiency [acute] with 
transient focal neurologic signs and symptoms; insufficiency of basilar, carotid, 
and vertebral arteries; spasm of cerebral arteries)
436 Acute, but ill-defined, cerebrovascular accident NOS; stroke
437.0 Cerebral atherosclerosis
437.3 Cerebral aneurysm, nonruptured
442.81 Artery of neck (aneurysm of carotid [common] [external] [internal])
442.82 Subclavian artery
446-446.7 Polyarteritis nodosa and allied conditions
780.2 Syncope and collapse (blackout; fainting; vasovagal)
781.2 Abnormality of gait (gait; ataxia; paralytic; staggering)
781.3 Lack of coordination (ataxia NOS; muscular incoordination)
781.4 Transient paralysis of limb (monoplegia, transient NOS)
782.0 Disturbance of skin sensation (numbness; paresthesia; tingling)
784.3 Aphasia
784.4 Other speech disturbance (dysarthria; dysphasia; slurred speech)
784.9 Other symptoms involving cardiovascular system (bruit [arterial])
900.00-900.9 Injury to blood vessels of head and neck
901.1 Innominate and subclavia arteries
996.1 Mechanical complication of vascular device, implant, and graft
996.7-996.99 Other complications of internal prosthetic device, implant, and graft 
(complications NOS, embolism, hemorrhage, pain, stenosis, or thrombus 
caused by [presence of] any device, implant and graft classifiable to 996.0-996.5)
998-998.9 Other complications of procedures, not elsewhere classified
V67.0 Examination after surgery
NOS, Not otherwise specified.
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 5 Passman et al 851
Appendix 2. ICD-9 codes that support medical necessity for venous duplex ultrasound
scans (CPT 93970, 93971), based on the LMRP as listed by the local Medicare carrier
(BlueCross/BlueShield of Tennessee and CIGNA HealthCare Medicare Administration) for
the state of Tennessee during 19993,5
ICD-9 code
415.1 Pulmonary embolism and infarction (pulmonary [artery] vein: apoplexy,
embolism, infarction [hemorrhagic], thrombosis)
415.19 Acute pulmonary heart disease, other
451-451.9 Phlebitis and thrombophlebitis (includes endophlebitis; inflammation, vein; 
periphlebitis; suppurative phlebitis)
454.0 Ulcer (varicose ulcer [lower extremity, any part], varicose veins with ulcer of 
lower extremity [any part] or of unspecified site; any condition classifiable to 
454.9 with ulcer or specified as ulcerated)
454.1 Inflammation (stasis dermatitis; varicose veins with inflammation of lower 
extremity [any part] or unspecified site; any condition classifiable to 454.9 with
inflammation of specified as inflamed)
454.2 Ulcer and inflammation (varicose veins with ulcer and inflammation of lower 
extremity [any part] or of ulcer and inflammation)
459.1 Postphlebitic syndrome
459.2 Compression of vein (stricture of vein; vena cava syndrome [inferior])
671.00-671.94 Venous complications in pregnancy and the puerperium
695.9 Unspecified erythematous condition (erythema NOS; erythroderma [secondary])
707.1 Ulcer of lower limbs, except decubitus (ulcer, chronic: neurogenic, or trophic of 
lower limb)
729.5 Pain in limb (to be used for pain with pressure)
729.81 Swelling of limb
747.60 Other anomalies of peripheral vascular system (absence, anomaly, or atresia of 
vein, not elsewhere classified; arteriovenous aneurysm [peripheral]; congenital 
aneurysm [peripheral], phlebectasia, or varix)
474.61 Gastrointestinal vessel anomaly
747.62 Renal vessel anomaly
747.63 Upper limb vessel anomaly
747.64 Lower limb vessel anomaly
747.69 Anomalies of other specified sites of peripheral vascular system
782.2 Localized superficial swelling, mass, or lump
782.3 Edema (localized edema NOS)
785.4 Gangrene (extremity)
786.00 Respiratory abnormality, unspecified
786.09 Other (respiratory: distress, insufficiency)
786.3 Hemoptysis (cough with hemorrhage; pulmonary hemorrhage NOS)
786.52 Painful respiration
786.59 Other (discomfort, pressure, or tightness in chest)
794.2 Pulmonary (abnormal lung scan)
903-903.9 Injury to blood vessels of upper extremity
904-904.9 Injury to blood vessels of lower extremity and unspecified sites
996.1 Mechanical complication of other vascular device, implant, and graft (mechanical 
complications involving surgically created arteriovenous fistula or shunt; dialysis
catheter; umbrella device, vena cava)
996.7 Other complications of internal prosthetic device, implant and graft (complication
NOS, embolism, fibrosis, hemorrhage, pain, stenosis, or thrombus caused by 
[presence of] any device, implant, and graft classifiable to 996.0-996.5)
996.71 Other complications of heart valve prosthesis
996.72 Other complications of other cardiac device
996.73 Other complications of renal dialysis device
996.74 Other complications of other vascular device
996.75 Other complications of nervous system device
996.76 Other complications of genitourinary device
996.77 Other complications of internal joint device
996.78 Other complications of internal orthopedic device
996.79 Other complications of internal prosthetic device
997.2 Peripheral vascular complications (phlebitis or thrombophlebitis)
998.2 Accidental puncture or laceration during procedure (accidental perforation by 
catheter or other instrument during a procedure on a blood vessel)
999.2 Other vascular complications (phlebitis, thromboembolism, or thrombophlebitis 
following infusion, perforation, or transfusion)
V67.0 Examination after surgery
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Appendix 3. ICD-9 codes that support medical necessity for lower-extremity arterial
Doppler scans (CPT 93923, 93924) based on the LMRP as listed by the local Medicare car-
rier (BlueCross/BlueShield of Tennessee and CIGNA HealthCare Medicare Administration)
for the state of Tennessee during 19993,5
ICD-9 code
440.0 Atherosclerosis of aorta
440.21 Atherosclerosis of the extremities with intermittent claudication
440.22 Atherosclerosis of the extremities with rest pain
440.23 Atherosclerosis of the extremities with ulceration
440.24 Atherosclerosis of the extremities with gangrene
440.29 Other atherosclerosis of native arteries of extremities
440.3 Atherosclerosis of bypass graft of the extremities
440.30 Atherosclerosis of unspecified graft
440.31 Atherosclerosis of autologous vein bypass graft
440.32 Atherosclerosis of nonautologous biologic bypass graft
442.0 Aneurysm of artery of upper extremity
442.3 Aneurysm of artery of lower extremity (aneurysm: femoral of popliteal artery)
443.0 Raynaud’s syndrome
443.1 Thromboangiitis obliterans (Buerger’s disease)
443.81 Peripheral angiopathy in diseases classified elsewhere
443.89 Other specified peripheral vascular diseases
443.9 Peripheral vascular disease, unspecified
444 Arterial embolism and thrombosis
444.0 Arterial embolism and thrombosis of abdominal aorta
444.1 Arterial embolism and thrombosis of thoracic aorta
444.21 Arterial embolism and thrombosis of upper extremity
444.22 Arterial embolism and thrombosis of lower extremity
444.81 Embolism and thrombosis of iliac artery
444.89 Embolism and thrombosis of other specified artery
444.9 Embolism and thrombosis of unspecified artery
447.0 Arteriovenous fistula, acquired
447.1 Stricture of artery
447.2 Rupture of artery
707.1 Ulcer of lower extremity, except decubitus
707.8 Chronic ulcer of other specified sites
785.4 Gangrene
903.00 Injury to axillary vessel(s), unspecified
903.01 Injury to axillary artery
903.02 Injury to axillary vein
903.1 Injury to brachial blood vessels
903.2 Injury to radial blood vessel
903.3 Injury to ulnar blood vessels
903.4 Injury to palmar artery
903.5 Injury to digital blood vessel
903.8 Other specified blood vessels of upper extremity
903.9 Unspecified blood vessel of upper extremity
904.0 Injury to common femoral artery
904.1 Injury to superficial femoral artery
904.2 Injury to femoral veins
904.3 Injury to saphenous veins
904.40 Injury to popliteal blood vessel(s), unspecified
904.41 Injury to popliteal artery
904.42 Injury to popliteal vein
904.50 Injury to tibial vessel(s), unspecified
904.51 Injury to anterior tibial artery
904.52 Injury to anterior tibial vein
904.53 Injury to posterior tibial artery
904.54 Injury to posterior tibial vein
904.6 Injury to deep planter blood vessels
904.7 Injury to other specified blood vessels of lower extremity
904.8 Injury to unspecified blood vessel of lower extremity
904.9 Injury to blood vessel, unspecified site
996.1 Mechanical complication of other vascular device, implant, and graft (mechanical 
complications involving aortic [bifurcation] graft [replacement] surgically created 
arteriovenous fistula or shunt, balloon [counterpulsation] device [intra-aortic])
996.7-996.99 Other complications of internal prosthetic device, implant, and graft (complication NOS, 
embolism, hemorrhage, pain, stenosis, or thrombosis caused by [presence of] any 
device, implant, and graft classifiable to 996.0-996.5)
998.1 Hemorrhage or hematoma complicating a procedure (hemorrhage of any site resulting 
from a procedure)
998.2 Accidental puncture or laceration during procedure (accident)
V67.0 Examination after surgery
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 5 Passman et al 853
Dr Robert Zwolak (Lebanon, NH). I would like to speak up
to say that this is a terribly important analysis because for most of
us if 20% of our vascular lab studies are not paid by Medicare then
our vascular laboratories are in the red, losing money for sure. For
example, in our laboratory, if we get paid for every study we just
barely make it into the black.
The observations I have are that local medical review policies
vary all over the country from some of the worst where there is a
huge percentage of denials to some of the best where appropriate
vascular laboratory studies are compensated by Medicare. I think
your experience probably falls in the middle from the worst to
best. It is difficult to deal with these payment policies because
they are made at the level of the individual Medicare carrier. It is
not as if HCFA central has made any rules about what lab studies
should be paid or what should not, except that screening as you
mentioned is really not paid. The question comes up, will the lab
get paid if you order a screening test on someone whose brother
had a stroke, and he has a 50-pack-year history of smoking, but
going into the study you do not have a diagnosis. That is initially
an asymptomatic patient, but coming out of the study he has a
50% to 70% stenosis, so suddenly you have a 433.1 diagnosis. Can
you apply that diagnosis in retrospect to get paid for that initial
study? The strictest interpretation of the regulations say no, but
many carriers will in fact pay for that diagnosis even though it was
made retrospectively.
At a national level, we are trying to put together a network
of carrier advisory committee vascular surgeon representatives to
deal with these local medical review policies because many labs are
being denied payment for performing appropriate studies.
Dr Marc A. Passman. Thank you for your comments. I will
just echo the fact that there is incredible variability between states
and it is important for us as vascular surgeons to know the regu-
lations per state. Of course these are the ICD-9 codes that are
listed for Tennessee, but obviously this problem extends at the
national level.
Dr Peter Gloviczki (Rochester, Minn). Could you tell us the
reason of the denial? The first denial was inadequate documenta-
tion, or it was an asymptomatic patient and it was considered as a
screening?
Dr Passman. In all fairness to Medicare, most of the reasons
for Medicare denial were inadequate understanding of the regu-
lations by the vascular lab that was submitting tests, as well as by
the providers ordering the test. The codes were submitted incor-
rectly, and it was only after recognizing the fact that these
Medicare denials were quite extensive that we went back and
looked at compliance. Frankly, these tests were appropriately
ordered; they were just not appropriately coded.
Dr Richard Spence (Birmingham, Ala). One of the problems
with denials comes from how many greedy hands get on the
Medicare money. I wonder if you know from your review if these
are all straight billing to Medicare or if they were through an
intermediary like an HMO. Our experience in New York until it
was stopped by a class action suit was that there was corporate
denial of claim payment to save money and float it in the market
and make interest. We are seeing now the same thing in a small
part in Alabama while waiting for a law to be passed through the
legislature that requires rapid payment. I wonder how many of
your denials actually went through the intermediary, because they
may deny things without any reason at all other than to save
themselves money.
Dr Passman. As far as I know, all the claims went through the
local medical carrier for Tennessee which was both Blue Cross and
Blue Shield for Medicare Part A and Cigna for Medicare Part B.
Dr Krishna Jain (Kalamazoo, Mich). The Society should look
into two other areas where we do not get reimbursed at all in the
vascular labs. We do about 20 to 30 tests a month for our cardiac
surgeons to map the saphenous vein as well as the radial artery.
There is no code for billing for mapping the saphenous vein or
the radial artery, so when you do that in your lab you cannot bill
for the procedures performed. I think we should probably look
into developing codes for that. Thank you.
Dr Passman. I would agree with that. What was not part of
this study is radial artery duplex mapping, which was universally
denied. What we did as a vascular lab is approach the local med-
ical carrier about getting those approved. Since the inception of
compliance rules in Tennessee in December of 1996, there have
been four or five revisions. Granted, it takes about a year or so
from the time you put your request in, but you can affect the
rules if you approach the local medical carrier with proper justifi-
cation why those tests need to be performed. Since then, we have
been able to get reimbursed for things like radial artery duplex
mapping.
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